Cancer Institute A national cancer institute
designated cancer center

Bioscience Screening Facility Shared Resource

http://htbc.stanford.edu

Facility Director: David E. Solow-Cordero, PhD
Faculty Advisor: James K. Chen, PhD

Contact

David E. Solow-Cordero, PhD
Director, BSF Shared Resource
Rm 0133A, CCSR Building
Stanford, CA 94305-5174
(650) 725-6002
Fax: (650) 725-6003
E-mail: desolow@stanford.edu
Lab:  Rm 0133, CCSR Building
(650) 736-7638

Overview

The Bioscience Screening Facility (BSF) Shared Resource provides researchers with the ability to run high-throughput chemical and genetic screens of biological systems.  Utilizing the BSF, Stanford Cancer Institute (SCI) researchers have the opportunity to discover chemical modulators of oncogenic mechanisms and to identify new therapeutic targets. Supported research activities include the use of: (1) chemical libraries for the identification of small molecule modulators of specific biological processes; (2) siRNA libraries for targeted gene silencing; and (3) cDNA libraries for in vivo or in vitro protein expression.  A variety of high-throughput instrumentation is also available for SCI researchers, including microplate liquid-handling robots, a high-throughput molecular biology workstation, multi-label microplate readers and a microplate-compatible epi-fluorescence microscope.  Reagents include over 130,000 small molecules for compound screens, 21,000 siRNA pools targeting the entire human genome and 15,000 cDNAs for gene expression screens.

Services

The Stanford BSF offers the following services. All are currently offered to SCI researchers.

1. Fully automated high-throughput screening of compound libraries for both enzyme/protein based assays and cell based assays, using the Caliper Life Sciences Staccato system.

2. Genomic siRNA screening with the siARRAY whole human genome siRNA library from ThermoFisher Scientific (formerly Dharmacon) targeting 21,000 genes, using the Agilent Bravo system.

3. High-content screening using the Molecular Devices ImageXpress Micro, a fully automated inverted epi-fluorescence microscope, with live-cell, phase contrast, brightfield, and robotic stacker options and image analysis using the MetaXpress software.

4. High-throughput molecular biology reagents and services including access to cDNA libraries (Human ORFeome collection) and high-throughput cDNA purifications using the Qiagen Biorobot 3000.

5. Assistance for high-throughput assay development, including cell culture, experiment design, robotic programming and Standard Operating Procedure drafting.

6. Assistance with screening data analysis including protocols, hit determination, and structure activity analyses using the Accelrys (formerly MDL) chemical database ISIS/HOST, Plate Manager, Assay Explorer and Report Manager.  

7. Use of microplate reader detection systems, including the Tecan Infinite M1000 (with dual injectors) and the Molecular Devices AnalystGT for fluorescence, fluorescence polarization, time-resolved fluorescence, absorbance and luminescence, and the Flexstation II 384, for kinetic fluorescence reads to measure calcium mobilization and ion channels.

8, Use of liquid handling robots, including the Sciclone ALH3000 (96- and 384-well pipetting), Velocity11 VPrep (96-well pipetting), Agilent Bravo System (96- and 384-well pipetting), Bio-Tek plate washers, Qiagen BioRobot 3000, and Matrix Wellmate and Titertek Multidrop microplate dispensers.

Operation

The BSF is located in the CCSR building North Wing, Room 0133, between the Transgenic Mouse Facility and the Immune Monitoring Core.  The ImageXpress Micro and a MetaXpress analysis computer are located in CCSR 0116.  Usual business hours 9 am to 5 pm, but after hours access to the resources can be obtained by contacting the BSF Director, Dr. David E. Solow-Cordero.

Procedures

Requests for services are fielded by the BSF Director, Dr. David E. Solow-Cordero.  Requests for instrumentation usage can be processed very quickly with the requirements of only a signed User Registration form and a short training session.  For potential screens, users will meet with Dr. Solow-Cordero to discuss all aspects of the proposed project.  Once a signed User Registration form is provided, initial experiments can be performed to test the feasibility of the screening assay.  Upon assay validation, users can request approval for access to the screening queue.

Stanford Medicine Resources:

Footer Links: